About us

Syntach AB is an innovation-driven company based in Lund, Sweden, which has close links to and extensive cooperation with several institutions at the University of Lund. The company was founded in 2012 with the idea of creating an entirely new class of cardiac support devices to improve the care of the rapidly growing amount of people with heart failure. Since a large number of patients needing cardiac support also suffer from mitral valve regurgitation, a leaking mitral valve, the company is also developing a minimally invasive device to correct this that can be used in combination with the cardiac support device, or on a standalone basis.


There are only a few alternative long-term therapies available for end-stage heart failure patients, including implantable mechanical devices and heart transplantation. Both alternatives have limitations. Hearts for transplanting are significantly limited by the availability of donors, require expensive and complex heart surgery, and subsequently heavy and expensive life-long immunosuppressive medication.

Available implantable mechanical heart pumps called Left Ventricular Assist Devices (LVADs) are expensive and cause a high risk of thrombosis due to their rapidly-moving thrombogenic parts in the bloodstream, as well as bleeding due to anticoagulation medication. Furthermore, they require complex open-heart surgery which also drastically influences the recovery time. Additionally, infections frequently occur due to the opening through the skin for cable connection, and patients experience a lower quality of life due to the external power source of the implanted device.

To address the current challenges, Syntach is developing a medical device for treating chronic left ventricular heart failure patients. Our patented innovation is an entirely new approach to heart failure treatment and works by restoring the natural function of the mitral valve plane that is reduced in heart failure patients. By providing a novel and effective product that eliminates the limitations of current treatment alternatives such as invasiveness, high costs, significant infection risk, thrombosis risk, external batteries and significant energy consumption, Syntach will have a unique place on the market. With our Syntach Cardiac Support device – the Syntach CS – we aim to increase patient survival rates, improve patients’ quality of life and lower healthcare care costs, meeting both the clinical and socio-economic needs.


Recent research at the University of Lund enabled the basic invention upon which Syntach was founded. Research revealed the importance of the scooping movement of the mitral plane; Two-thirds of the heart’s pumping function is generated by this movement, which is reduced in heart failure patients.

The invention is a fully implanted device, the Syntach CS (Cardiac Support). Instead of bypassing the left ventricle, like present ventricular assist devices (LVADs) do, the Syntach CS supports the mitral plane’s natural movement. This is an entirely new approach with several advantages.

The Syntach CS consists of a drive unit, a ring-shaped anchor placed in the mitral plane, an additional anchor for the heart apex region and an implantable power unit. Electrical power is supplied by a fully implantable and rechargeable battery under the skin. The system also includes a wrist communication device for controlling the device’s function and battery status. The mitral anchor will provide means for simultaneous annuloplasty for patients who suffer heart failure and mitral insufficiency. Up to 45% also suffer from mitral valve regurgitation of the heart failure population.


Syntach was founded in 2012 by Professor J.O. Solem from the University of Lund and Tor Peters a Swedish entrepreneur based in Switzerland.

Jan Otto Solem

Well-known Scandinavian cardiac surgeon specialized in heart and lung transplantation and assist devices. Worked with and implanted all the existing assist devices.

Tor Peters

Main investor, CEO of the Occlutech Group, with over 30 years’ experience in senior positions and board roles at various med-tech companies.